
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES AND EXCHANGE ACT OF 1934**

Date of report (date of earliest event reported): January 18, 2005

COMMONWEALTH BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

Virginia
(State or Other Jurisdiction
of Incorporation)

001-13467
(Commission File Number)

56-1641133
(IRS Employer
Identification No.)

601 Biotech Drive
Richmond, Virginia 23235
(Address of principal executive offices)

Registrant's telephone number, including area code: (804) 648-3820

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

- (a) Financial statements of businesses acquired.
- (b) Pro forma financial information.
Not Applicable.
- (c) Exhibits.
 - 99.1 Press Release, dated January 17, 2005, announcing the receipt of new contract awards.

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

COMMONWEALTH BIOTECHNOLOGIES, INC.

By: /s/ Robert B. Harris, Ph.D.

Robert B. Harris, Ph.D.
President and Chief Executive Officer

Dated: January 18, 2005

EXHIBIT INDEX

<u>Number</u>	<u>Description of Exhibit</u>
99.1	Press Release, dated January 17, 2005, announcing the receipt of new contract awards.

For further information, contact:

Dr. Robert B. Harris
President/CEO, CBI
Phone: 800 735 9224
Fax: 804 648 2641

Commonwealth Biotechnologies, Inc. Announces Contract Signings

Includes First Major Contract for new FIL Division

RICHMOND, VA (January 17, 2005) - Commonwealth Biotechnologies, Inc. (NASDAQ SmallCap Market: CBTE), today reported receipt of new contract awards in the December, '04 – January, '05 period totaling nearly \$1.1 million, including receipt of the first contract for CBI's new division, Fairfax Identity Labs, FIL. Work on all these new programs has been initiated, and the bulk of these new revenues will be recognized within 2005.

Among the group of new contracts is an extension of CBI's program for screening mail destined for delivery to the Pentagon for the presence of toxins and pathogens, and quality control assessment of individual pharmaceutical preparations on behalf of a government customer. The new contract for FIL is valued at over \$500,000 and is for accessioning forensic case samples for a state laboratory, which due to confidentiality issues, must remain unnamed.

CBI announced completion of the acquisition FIL on December 15, 2004. The transfer of all FIL equipment and personnel to CBI's facility in Richmond was completed the last week in December, and CBI's new DNA reference laboratory was outfitted and came on-line almost immediately.

"As previously announced, the acquisition of FIL is expected to add to CBI's revenue stream beginning in the first quarter of 2005," explained Thomas R. Reynolds, Executive Vice President for Science and Technology, CBI who is directly responsible for management oversight of the FIL Division. "In addition to the revenues anticipated from the acquisition of FIL's existing assets, this new contract represents a significant accomplishment for the division which has been in place for less than a month. Receipt of this contract is testament to the excellent reputation of the staff of FIL and Dr. Kelly, who is now the Director of CBI's new FIL division.

#

About CBI

Commonwealth Biotechnologies, Inc. is a comprehensive provider of contract research and development services to the global biotechnology industry, academic institutions, government agencies, and pharmaceutical companies. It offers cutting-edge expertise and a complete array of the most current analytical and synthetic chemistries and biophysical analysis technologies, many of which are not available from other commercial sources. Services include DNA analyses, genomics, proteomics, biochemical analyses, mass spectral analysis, microbiological services, pathogen testing, food microbiology, peptide services, protein sequencing and drug discovery, and through its FIL division, CBI offers comprehensive genetic identity testing, including paternity, forensic, and CODIS analyses. CBI is accredited by the American Association of Blood Banks, CLIA, and the National Forensic Science Technology Council, and operates fully accredited BSL-3 laboratory. For more information, visit CBI on the web at www.cbi-biotech.com and visit FIL at www.fairfaxidlab.com.

#

Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in the Company's filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. No statement herein should be considered an offer of any securities. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Specifically, there can be no guarantee that CBI will continue to see positive trends in financial performance and there can be no guarantee that CBI will compete effectively for additional contracts. In addition, there can be no guarantee that CBI will receive all fees anticipated under the contracts referenced herein. A number of factors, including customer demand, industry trends, armed conflict, and terrorist activities could alter these trends referenced herein. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.